Inhibition of ALK5 as a new approach to treat liver fibrotic diseases

Drug News and Perspectives

Volumn 19, Issue 2, 2006, Pages 85-90

  De Gouville, Anne Charlotte ^a,b   Huet, Stephane ^a  

^a GLAXOSMITHKLINE   (United States)

^b GSK   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYTOKINE RECEPTOR ANTAGONIST; DECORIN; GW 6604; INTERLEUKIN 1; MESSENGER RNA; PROTEIN KINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ATHEROSCLEROTIC PLAQUE; CELL CYCLE REGULATION; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; KIDNEY FIBROSIS; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; PROTEIN URINE LEVEL; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIVER CIRRHOSIS; PYRAZOLES; PYRIDINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

EID: 33646496008     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2006.19.2.977444     Document Type: Review

References (42)

1. Benyon, R.C. and Arthur, M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001, 21: 373-84.
2. Duchatelle, V., Marcellin, P., Giostra, E. et al. Changes in liver fibrosis at the end of Interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol 1998, 29: 20-8.
3. Dienstag, J.L., Goldin, R.D., Heathcote, E.J. et al. Histological outcomes during long-term lamivudine therapy. Gastroenterology 2003, 124: 105-17.
4. Li, D. and Friedman, S. Liver fibrogenesis and the role of hepatic stellate cells: new insight and prospects for therapy. J Gastroenterol Hepatol 1999, 14: 618-33.
5. Gressner, A.M. Transdifferentiation of hepatic stellate cells (ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int 1996, 54: S39-S45.
6. Milani, S., Herbst, H., Schuppan, D., Kim, K.Y., Riecken, E.O. and Stein, H. Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology 1990, 98: 175-84.
7. Geerts, A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001, 21: 311-35.
8. Sun, M.A., Wang, B.E., Annoni, G., Degliesposti, S., Biempica, L. and Zern, M. A. Two rat models of hepatic fibrosis. A morphologic and molecular comparison. Lab Invest 1990, 63: 467-75.
9. Coimbra, T., Wiggins R., Noh, J.W., Merrit, S. and Phan, S.H. Transforming growt factor-beta production in anti-glomerular basement membrane disease in the rabbit. Am J Pathol 1991, 138: 223-34.
10. Jones, C,L., Buch, S., Post, M., McCulloch, L., Liu, E. and Eddy, A.A. Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis. Kidney Int 1991, 40: 1020-31.
11. Bayer, E.M., Yingling, J.M., Howe, D.J. et al. Transforming growth factor-beta 1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J Hepatol 1994, 28: 803-11.
12. Border, W.A. and Noble, N.A. Transforming growth factor beta in tissue ftbrosis. N Engl J Med 1994, 331: 1286-92.
13. Broekelmann, T.J., Limper, A.H., Colby, T.V. and McDonald, J.A., Transforming growthfactor beta1 is present at site of extracellular matrix gene expression in human pulmonary fibmsis. Proc Natl Acad Sci 1991, 88: 6642-6.
14. Paradis, V. Mathurin, P., Laurent, A. et al. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol 1996, 49: 998-1004.
15. Kanzler, S., Baumann, M., Schimacher, P. et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue level of transforming growth factor-beta. J Viral Hepat 2001, 8: 430-7.
16. Sanderson, N., Factor, V. Nagy, P. et al. Hepatic expression of mature transforming growth factor beta1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci 1995, 92: 2572-6.
17. Kopp, J.B., Factor, V., Mozes, M. et al. Transgenic mice with increased plasma levels of TGF-beta1 develop progressive renal disease. Lab Invest 1996, 74: 991-1003.
18. Ziyadeh, F. Hoffman, B., Han, D.C. et al. Long term prevention of reanl insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci 2000, 97: 8015-20.
19. George, J., Roulot, D., Koteliansky, V.E. and Bissel. D.M. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci 1999, 12: 719-24.
20. Kolb, M., Margetts, P.J., Galt T. et al. Transcient gene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med 2001, 163: 770-7.
21. Border, W.A., Noble, N.A., Yamamoto, T. et al. Natural inhibitor of transforming growth factor beta protects against scarring in experimental kidney disease. Nature 1992, 360: 361-5.
22. Isaka, Y., Brees, D.K., Ikegaya, K., Imai, E., Noble, N.A. and Border, W.A. Gene therapy by skeletal muscle expression of decorin prevents fibroitic disease in rat kidney. Nat Med 1996, 2: 418-23.
23. Nakamura, T., Sakata, R., Ueno, T., Sata, M. and Ueno, H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000, 32: 247-55.
24. Qi, Z., Atsuchi, N., Ooshima, A., Takeshita. A. and Ueno, H. Blockade type beta transforming growth factor signaling prevents liverfihrosis and dysfunction in the rat. Proc Natl Acad Sci 1999, 96: 2345-9.
25. Arias, M., Sauer-Lehnen, S., Treptau, J. et al. Adenoviral expression of a transforming growth factor beta-1 antisense mRNA is effective in preventing liver fibrosis in bile duct ligated rats. BMC Gastroenterol 2003, 3: 29.
26. Schnur, J., Olah, J., Szepesi, A., Nagy, P. and Thorgeirsson, S.S. Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol 2004, 16: 127-33.
27. Lebrin, F. Deckers, M., Bertolino, P. and Ten Dijke, P. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005, 65: 599-608.
28. Derynck, R. and Zhang, Y.E Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 2003, 425: 577-84
29. Laping, N., Grygielko, E., Mathur, A. et al. Inhibition of transforming growth factor (TGF)beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type 1 receptor kinase activity: SB-431542. Mol Pharmacol 2002, 62: 58-64.
30. De Gouville, A.-C., Boullay, V., Krysa G. et al. Inhibition of TGF-beta signaling by an ALKS inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 2005, 145: 166-77.
31. Neumann-Haefelin, C., Blum, H.E., Chisari, F.V. and Thimme, R. T cell response in hepatitis C virus infection. J Clin Virol 2005, 32: 75-85.
32. Von Boehmer, H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005, 6: 338-44.
33. Thimme, R., Bukh, J., Spangenberg, H.C. et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002, 99: 15661-8.
34. Grygielko, E.T., Martin, W.M., Tweed, C. et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type 1 receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 2005, 313: 943-51.
35. Bonniaud, P., Margetts, P.J., Kolb, M. et al. Progressive transforming growth factor beta1 induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Care Med 2005, 171: 889-98.
36. Underwood, D.C., Osborn, R.R., Grygielko, E.T., and Laping, N.J. SB-525334, a novel TGF-beta type 1 receptor kinase inhibitor, prevents ans reverses Bleopmycin-induced pulmonary fibrosis in the rat. Am Thorac Soc (Seattle) 2003, Abst.
37. Tojo, M., Hamashima, Y., Hanyu, A. et al. The ALK5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci 2005, 96: 791-800.
38. Yingling, J.M., Blanchard, K.L. and Sawyer, J.S. Development of TGF-beta signaling inhibitors for cancer therapy. Nat Rev Drug Discov 2004, 3: 1011-22.
39. Mallat, Z., Gojova, A., Marchiol-Fournigault, C. et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001, 89: 930-1.
40. Goumans, M.J., Valdimarsdottir, G., Itoh, S. et al. Activin receptor-like kinase (ALK-1) is an antagonistic mediator of lateral TGF-beta/ALK5 signaling. Mol Cell 2003, 12: 817-28.
41. Inman, G.J., Nicolas, F.J., Callahan, J.F. et al. SB 431542 is apotent and specific inhibitor of transforming growth factor-beta superfamily type 1 activin receptor-like kinase (ALK) receptor ALK4, ALK5, and ALK7. Mol Pharmacol 2002, 62: 65-74.
42. DaCosta, Byfield, S., Major, C., Laping, N.J. and Roberts. A.B. SB-505124 is a selective inhibitor of transforming growth factor-B type 1 receptors ALK4, ALK5 and ALK7. Mol Pharmacol 2004, 65: 744-52.